Contribution: Industrial Research Assistance Program – Contributions to Firms
Fedora Pharmaceuticals Inc.
$245,000.00
Development of an orally-active antibiotic to treat antimicrobial resistant (AMR) bacterial infections
FY 2018-19 · 2018-04-01
Summary
Antimicrobial resistance bacteria (AMR) have a significant impact on mortality, hospital stay and associated costs. The overall objectives of the project are to prepare new oral antibiotics capable of killing AMR and treating serious and life-threatening infections in patients.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Edmonton|Edmonton, Alberta, Canada
Recipient Type
For-profit organization
Business Number
822507489
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 1 | 2018-04-01 | 2018-19 | $250,000.00 |
| 2 | 2018-04-01 | 2018-19 | $250,000.00 |
| 3 | 2018-04-01 | 2018-19 | $245,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is -5,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de - 5 000 dollars.
Agreement End Date
2020-03-31
Agreement Number
898980
Agreement Start Date
2018-04-01
Agreement Title
Development of an orally-active antibiotic to treat antimicrobial resistant (AMR) bacterial infections
Agreement Title (French)
Développement d'un antibiotique actif par voie orale pour traiter les infections bactériennes résistantes aux antimicrobiens
Agreement Type
Contribution
Agreement Value
$245,000.00
Amendment Date
2020-02-24
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Antimicrobial resistance bacteria (AMR) have a significant impact on mortality, hospital stay and associated costs. The overall objectives of the project are to prepare new oral antibiotics capable of killing AMR and treating serious and life-threatening infections in patients.
Description (French)
Les bactéries de résistance aux antimicrobiens (RAM) ont un impact significatif sur la mortalité, le séjour à l'hôpital et les coûts associés. Les objectifs généraux du projet sont de produire de nouveaux antibiotiques oraux capables de tuer la RAM et de traiter les infections graves et potentiellement mortelles pour les patients.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Centre
Federal Riding (French)
Edmonton-Centre
Federal Riding Number
48014
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
822507489
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Fedora Pharmaceuticals Inc.
Recipient Postal Code
T5H 0L9
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2018-2019-Q4-898980
